Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 158

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4
Chunk 158
---
. The 16 patent applications are pending in the U. S., Europe,
Taiwan, China, Korea, Japan, India, Singapore, Australia, Canada, Mexico, Russia, ARIPO, South Africa, Israel and Hong Kong. These patents
or patents issuing from these pending applications will begin to expire in 2041, exclusive of possible patent term adjustments or extensions
or other forms of exclusivity.

We have three issued patents,
and 15 pending patent applications, relating to an applicator for delivery of radiotherapy sources to a tumor of a patient through an
elongate needle. The three issued patents have been issued in the U. S., South Africa, and Australia. The 15 patent applications are pending
in the U. S., Europe, Taiwan, China, Korea, Japan, India, Singapore, Australia, Canada, Mexico, Russia, ARIPO, Israel and Hong Kong. These
patents or patents issuing from these pending applications will begin to expire in 2041, exclusive of possible patent term adjustments
or extensions or other forms of exclusivity.

We have six issued patents,
and nine pending patent applications, relating to a template assembly to grasp a body organ during radiotherapy. The six issued patents
have been issued in the U. S., Japan, Australia, South Africa, Hong Kong and China. The nine patent applications are pending in the U. S.,
Korea, India, Singapore, Canada, Taiwan, Mexico, Russia and ARIPO. These patents or patents issuing from these pending applications will
begin to expire in 2041, exclusive of possible patent term adjustments or extensions or other forms of exclusivity.

We have two issued patents,
and 15 pending patent applications, including two allowed patent applications, relating to a modified Alpha DaRT source with higher activity
levels and lower desorption probability for enhanced effects of beta radiation. The two issued patents have been issued in the U. S. and
South Africa. The 15 patent applications are pending in the U. S., Europe, Taiwan, Japan, China, Korea, India, Singapore, Australia, Canada,
Mexico, Russia, ARIPO, Israel and Hong Kong, of which a U. S. patent application and an Australian patent application have been allowed.
These patents or patents issuing from these pending applications will begin to expire in 2042, exclusive of possible patent term adjustments
or extensions or other forms of exclusivity.

We have three issued patents
and 15 pending patent applications, including one allowed